Novartis India Ltd. (BSE: 500672) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹3,910 Cr, it ranks #949 by market cap among the 6,197 Indian listed companies on FinBizNet, and #18 of 63 in Pharmaceuticals. At ₹1,722.40 (as of 16 Nov 2026), the share price is 33.5% below its 52-week high of ₹2,588.80 and 156.2% above its 52-week low of ₹672.25.
| Current Price | ₹1,722.40 |
|---|---|
| Market Cap | ₹3,910 Cr |
| BSE Code | 500672 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 42.1 |
| Return on Equity | 11.63% |
| Return on Assets | 6.13% |
| 52-Week Range | ₹672.25 – ₹2,588.80 |
| 3-Month Price Change | -1.8% |
| Beta (1Y) | -0.02 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.novartis.in |
| Revenue | ₹104 Cr |
|---|---|
| Net Profit | ₹32 Cr |
| Net Margin | 31.0% |
| EPS (Basic) | ₹13.05 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Novartis India Ltd. reported revenue of ₹104 Cr in Q1 FY27, up 18.6% from ₹88 Cr in Q1 FY26 and up 14.6% from ₹91 Cr in Q4 FY26. It posted a net profit of ₹32 Cr for the quarter, against a net profit of ₹28 Cr in Q1 FY26 (up 16.6%). Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹84 Cr (Q4 FY25) to ₹104 Cr (Q1 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹104 Cr | ₹32 Cr | 31.0% |
| Q4 FY26 | ₹91 Cr | ₹25 Cr | 27.9% |
| Q3 FY26 | ₹86 Cr | ₹16 Cr | 18.7% |
| Q2 FY26 | ₹90 Cr | ₹24 Cr | 26.8% |
| Q1 FY26 | ₹88 Cr | ₹28 Cr | 31.5% |
| Q4 FY25 | ₹84 Cr | ₹29 Cr | 34.9% |
Standalone figures (₹ crore, XBRL filings).
Delivery averaged 50.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. The company is a subsidiary of Novartis AG.
1. Pharmaceutical Business-This segment offers drugs and pharmaceutical products. 2. Generics-0 3. OTC-0 4. Animal Health-0
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Novartis India Ltd. | ₹3,910 Cr | 42.1 | 11.63% | ₹104 Cr | — |
Listed by market capitalisation. Ratios are shown for context only.
Novartis India Ltd. is trading at ₹1,722.40, with a market capitalisation of ₹3,910 Cr.
Novartis India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Novartis India Ltd. has a P/E of 42.1 and a return on equity of 11.63%.
Novartis India Ltd. is listed on the BSE under the scrip code 500672.
In Q1 FY27, Novartis India Ltd. reported revenue of ₹104 Cr and net profit of ₹32 Cr, with basic EPS of ₹13.05 (standalone, parsed from the company's exchange filing).
Novartis India Ltd. reported revenue of ₹104 Cr in Q1 FY27, up 18.6% from ₹88 Cr in Q1 FY26 and up 14.6% from ₹91 Cr in Q4 FY26.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.